Close

FDA approves Paragonix’s next generation donor lung preservation system

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

The US FDA has granted approval for Paragonix Technologies’ next-generation donor lung preservation system, BAROguard.

The system integrates the company’s advanced hypothermic preservation technology with automated, continuous and active control of airway pressure.

This guarantees the maintenance of an optimal temperature range and a clinically recommended range of inflation pressure for donor lungs throughout the transportation from donor to recipient patient.

In the present clinical practice, donor lungs are preserved and transported in an inflated state from the donor to the recipient site.

The existing methods for organ recovery fail to maintain and control lung inflation pressures within the clinically recommended 12cm-15cm Hâ‚‚O range.

A large portion of donor lungs are transported by aircraft. This method of transportation is said to expose the lungs to potential pressure changes due to the varying ambient conditions.

This increase in pressure has been observed in studies on respiratory care and it raises the possibility of a greater risk for pulmonary barotrauma.

Paragonix CEO and president Dr Lisa Anderson said: “At Paragonix, we believe that transplant surgeons should have maximum control over the organ transplant process.

“BAROguard now offers automated active control over donor lung airway pressures and automated donor lung temperature control, both of which are continuously reported in real-time to the transplant team.

“The FDA clearance of BAROguard is a major step in providing transplant teams with leading technology to enhance organtransplantation outcomes.”

Latest stories

Related stories

Who Is and Isn’t a Good Candidate for LASIK Surgery?

In the decades since its FDA approval, LASIK eye...

The Three Top Benefits of Opting for an Innovative Healthcare Practice

An innovative healthcare practice offers improved patient care through...

Remote Patient Monitoring: A Cost-Effective Solution for Patients and Health Facilities

Remote patient monitoring services are reshaping the healthcare landscape,...

PatientPoint improves health outcomes with new MyHealthTeam partnership

PatientPoint, one of the country’s leading digital health companies...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back